文献速递免疫规划职业卫生

SARS-CoV-2 BNT162b2 mRNA疫苗的体液免疫应答:来自大型医护人员队列的真实世界数据

Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
PubMed 文献 · Vaccine · 2021-12-11

本研究在4264名医护人员中,于接种BNT162b2 mRNA疫苗前(T0)及接种后15天(T1)和90天(T2)检测抗SARS-CoV-2 IgG。接种后15天IgG总体中位滴度显著升高至21.7×10³ AU/mL,女性及年轻者滴度更高;接种后3个月IgG滴度下降6.3倍,但接种前滴度较高者维持较高水平。结论支持追踪体液免疫动力学以发现病毒易感性并适时实施再接种。

要点

  • 接种BNT162b2后15天抗SARS-CoV-2 IgG总体中位滴度显著升高至21.7×10³ AU/mL。
  • 女性及较年轻医护人员接种后15天抗体滴度更高,且随年龄每增加10岁滴度下降。
  • 接种后3个月抗SARS-CoV-2 IgG滴度较15天时下降6.3倍。

核心结论

  • 真实世界接种后数据证实抗SARS-CoV-2 IgG滴度频繁且升高,与高保护率相关。
  • 女性及年轻参与者在接种后15天滴度更高,尽管15至90天显著下降,接种前滴度较高者在后续时间点维持较高水平。
  • 作者认为这些发现支持追踪体液免疫动力学以发现病毒易感性并最终实施再接种,尤其在体液免疫应答较低的人群中。

研究设计与样本

  • 研究纳入4264名医护人员,于接种BNT162b2 mRNA疫苗前(T0)及接种后15天(T1)和90天(T2)采集外周血。
  • 采用Quant SARS-CoV-2 IgG II化学发光微粒子免疫分析法(CMIA)检测抗刺突IgG、受体结合域(RBD)及SARS-CoV-2 S1亚单位。

主要发现

  • T0时96.8%(n=4129)的参与者抗SARS-CoV-2 IgG抗体为非反应性。
  • 完成接种后15天,IgG总体中位滴度显著升高至21.7×10³ AU/mL。
  • 单因素和多因素logistic回归分析均显示,女性抗体水平高于男性,且不依赖于年龄。
  • 各年龄组间滴度存在显著差异,年龄每增加10岁滴度下降。
  • 完成接种后3个月,抗SARS-CoV-2 IgG滴度下降6.3倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SARS-CoV-2 pandemic was responsible for the death of millions of people around the world, which accelerated the study of vaccines. The BNT162b2 mRNA COVID-19 is a messenger RNA vaccine that encodes the spike protein of the virus. However, the duration of the protection conferred by this vaccine and factors associated with immune responses require validation in large cohorts. METHODS: Here, we present data of humoral immune response to vaccination in4264 healthcare workers, tested before (T0) and 15 and 90 days (T1 and T2, respectively) following vaccination.Peripheral blood was collected for immunological analysis using the Quant SARS-CoV-2 IgG II Chemiluminescent Microparticle Immunoassay (CMIA) to determine anti-spike IgG, receptor binding domain (RBD), S1 subunit of SARS-CoV-2. FINDINGS: At T0, 96·8% (n = 4129) of participants had IgG antibodies non-reactive to anti-SARS-CoV-2. Fifteen days after completing the vaccination, the IgG overall median titer was significantly elevated (21·7x103AU/mL). Both for uni- and multivariate logistic regression analyses women presented higher antibody levels than men, independent of age. Titers were significantly altered among age groups, decreasing by each increase in 10-year of age. At 3 months after completing the vaccination, anti-SARS-CoV-2 IgG titers were 6·3-fold diminished. This real-world post-vaccination data confirmed production of a frequent and elevated anti-SARS-CoV-2 IgG titers, associated with high protection rates. Females and younger participants had higher titer 15 days after vaccination, and despite the significant reduction from 15-to-90 days, those with higher pre-vaccination titers maintained higher levels throughout the remaining timepoints. INTERPRETATION: These findings support the need to track humoral immunity kinetics to uncover viral susceptibility and eventually implement re-vaccination, particularly in groups prone to lower humoral immune response. FUNDING: No external funding was received to conduct this study.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Oliveira-Silva J, Reis T, Lopes C, et al. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. Vaccine. 2021. PMID: 34952755. doi:10.1016/j.vaccine.2021.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。